Overview

Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
This trial was conducted in Europe. The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S